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Abstract
Background: We analyzed the effects of insulin therapy, age and gender on the risk of ischemic heart disease
(IHD) and cerebrovascular accident (CVA) according to glycemic control.
Methods and Results: We performed a prospective cohort study (Japan Cholesterol and Diabetes Mellitus Study)
of type 2 diabetes patients (n = 4014) for 2 years. The primary endpoint was the onset of fatal/non-fatal IHD and/
or CVA, which occurred at rates of 7.9 and 7.2 per 1000 person-years, respectively. We divided diabetic patients
into four groups based on age (≤ 70 and > 70) and hemoglobin A1C levels (≤ 7.0 and > 7.0%). Multiple regression
analysis revealed that IHD was associated with high systolic blood pressure and low HDL-C in patients under 70
years of age with fair glycemic control and was associated with low diastolic blood pressure in the older/fair
group. Interestingly, insulin use was associated with IHD in the older/poor group (OR = 2.27, 95% CI = 1.11-5.89;
p = 0.026) and was associated with CVA in the older/fair group (OR = 2.09, 95% CI = 1.06-4.25; p = 0.028). CVA was
associated with lower HDL-C and longer duration of diabetes in younger/poor glycemic control group. Results by
stepwise analysis were similar. Next, patients were divided into four groups based on gender and diabetic control
(hemoglobinA1C < or > 7.0%). Multiple regression analysis revealed that IHD was associated with high systolic
blood pressure in male/fair glycemic control group, age in male/poor control group, and short duration of diabetic
history in females in both glycemic control groups. Interestingly, insulin use was associated with IHD in the male/
poor group(OR = 4.11, 95% CI = 1.22-8.12; p = 0.018) and with CVA in the female/poor group(OR = 3.26, 95% CI =
1.12-6.24; p = 0.02). CVA was associated with short duration of diabetes in both female groups.
Conclusions: IHD and CVA risks are affected by specific factors in diabetics, such as treatment, gender and age.
Specifically, insulin use has a potential role in preventing IHD but may also be a risk factor for CVA among the
diabetic elderly, thus revealing a need to develop improved treatment strategies for diabetes in elderly patients.
The Japan Cholesterol and Diabetes Mellitus Study was formulated to evaluate them(Umin Clinical Trials Registry,
clinical trial reg. no. UMIN00000516; http://www.umin.ac.jp/ctr/index.htm).
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Elderly patients with type 2 diabetes mellitus (T2DM)
have much higher risks of ischemic heart disease (IHD)
and cerebrovascular accident (CVA) compared to
younger diabetic patients. Because of these risks, diabetes
may shorten an individual’s life span by approximately 10
years [1]. A considerable number of studies have assessed
IHD and CVA risk factors in culturally diverse groups of
diabetic patients less than 70 years of age. With regard to
glycemic control, a recent meta-analysis of several large
clinical studies revealed that intensive and strict glycemic
control was more effective than standard control for pre-
venting IHD [2]. This review analyzed five trials, includ-
ing the United Kingdom Prospective Diabetes Study
(UKPDS), Action to Control Cardiovascular Risk in Dia-
betes (ACCORD), and Action in Diabetes and Vascular
Disease: Preterax and Diamicron Modified Release Con-
trolled Evaluation (ADVANCE). The meta-analysis study
concluded that intensive glucose control [decreasing
hemoglobin A1C (HbA1C) levels by 0.9%] was superior
to standard control for preventing IHD. However, inten-
sive glucose control did not seem to have any effect on
stroke rates or overall survival [2-5]. Furthermore, most
studies focused exclusively on patients under the age of
70 and did not examine elderly diabetic patients. Addi-
tionally, the authors did not evaluate whether specific
diabetes treatments, such as insulin, had any effect on the
risk of IHD and CVA.
The Japanese population has lower rates of IHD and
higher rates of CVA than the U.S. and European popu-
lations [6]. However, the rate of IHD is much higher
among Japanese diagnosed with diabetes [6,7]. Although
it has been shown that elderly diabetic individuals have
a higher risk of IHD than younger, non-diabetic
patients, there is insufficient evidence regarding the
a s s o c i a t i o n sb e t w e e na g e ,d i a b e t i cc o n t r o l ,C V A ,a n d
IHD [8]. The present study, the Japan-CDM (Japan
Cholesterol and Diabetes Mellitus Investigation), was a
nationwide observational cohort study that enrolled
4,014 Japanese individuals with diabetes [7]. We recently
reported the possibility of a change in the relationship
between atherosclerotic risk factors and IHD or CVA
based on age [9]. In other words, we identified a signifi-
cant relationship between lower HDL or higher LDL
cholesterol levels and the occurrence of IHD in subjects
older than 65 years old. Lower HDL cholesterol was
also significantly related to CVD in subjects over 65
years of age and especially in those older than 75. Lower
HDL cholesterol is an important risk factor for IHD and
CVD, especially in diabetic elderly individuals. Based on
these data, the goal of this study is to evaluate the rela-
tionships between age, diabetic control, CVA and IHD
in Japanese T2DM patients.
Methods
Patients
We recruited diabetic individuals examined at 40 institu-
tions throughout Japan between September 2004 and
March 2005. Patients who had experienced previous
myocardial infarctions or cerebrovascular accidents
requiring hospitalization were excluded from the study.
Other exclusion criteria included the following: a history
of or complications related to serious heart disease (such
as acute heart failure); serious hepatic or renal disease,
such as non-compensated liver cirrhosis and chronic
renal failure requiring hemodialysis; malignancy; inten-
tion to undergo surgery; any illness with a poor prog-
nosis; and the recruiting physician’sj u d g m e n tt h a ta
patient was inappropriate for inclusion in the study.
Study design
This multicenter prospective longitudinal cohort study
included 4,014 diabetic individuals examined on a con-
secutive outpatient basis (1,936 women and 2,078 men;
mean age = 67.4 ± 9.5 years, range = 35-83 years, med-
ian = 70.4 years). The one-year and two-year follow-up
rates were 98.2% and 92.3%, respectively (Figure 1). Pri-
mary endpoints were the onset of IHD (comprising fatal
or nonfatal myocardial infarction; development of
unstable angina; or the need for coronary revasculariza-
tion procedures, either coronary artery bypass grafting
or percutaneous coronary intervention because of angina
or an acute coronary syndrome) or CVA (stroke with
neurological deficit, except transient ischemic attack).
Secondary endpoints were sudden cardiac death due to
causes other than myocardial infarction, transient
ischemic attack, subarachnoid hemorrhage and all-cause
mortality. We collected blood samples from the patients
to evaluate their plasma lipid levels, blood glucose levels
and HbA1C levels during the same month each year.
Informed consent was obtained from all subjects partici-
pating in the study. The study was approved by the
Institutional Review Boards of the participating hospitals
and the relevant safety monitoring boards [10]. The
guidelines of the Japan Atherosclerosis Society, which
state that LDL values should be less than 120 mg/dL
and HDL values should be higher than 40 mg/dL in dia-
betic individuals, and the diagnostic criteria for T2DM
of the American Diabetes Association were used [11,12].
All reported events were confirmed by the organizing
committee.
Group allocation by age and glycemic control
We investigated the relationships between age, diabetic
control, IHD, and CVA. Because the median age and
hemoglobin A1C values of the patients in this study
were 70.4 years and 7.0%, respectively, we divided the
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and hemoglobin A1C levels (≤ 7.0 and > 7.0%). The
four groups were as follows: 1) NF: under 70 years of
age with fair glycemic control (n = 870); 2) NP: under
70 years of age with poor glycemic control (n = 1,072);
3) OF: over 70 years of age with fair glycemic control
(n = 923); and 4) OP: over 70 years of age with poor
glycemic control (n = 1,149).
Group allocation by gender and glycemic control
We investigated the relationships between gender, diabetic
control, IHD, and CVA. We divided the patients into four
Figure 1 Trial design and cardiovascular events that occurred after the first and second years among the diabetic individuals included
in the study. AMI: acute myocardial infarction, ACS: acute coronary syndrome, CVA: cerebrovascular accident (stroke), ASO: arteriosclerosis
obliterans, CHF: congestive heart failure.
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and > 7.0%). The four groups were as follows: 1) MF:
males with fair glycemic control (n = 1063); 2) MP: males
with poor glycemic control (n = 950); 3) FF: females with
fair glycemic control (n = 859); and 4) FP: females with
poor glycemic control (n = 1,142).
Statistics
Results are presented as means ± SD (standard deviation)
of the data analyzed. All statistical analyses were performed
using JMP (version 7, SAS Institute Inc., Cary, NC). The
incidence of IHD and CVA were analyzed according to
age, which was stratified as 70 years or younger vs. older
than 70 years. We used the chi-square test and Fisher’s
exact test for categorical comparisons of the data. Differ-
ences in the means of continuous measurements were
tested using the Mann-Whitney U test. We selected possi-
ble significant predictors by conducting a univariate logistic
regression analysis (P < 0.10) and performed multiple logis-
tic regression analysis to identify important risk factors for
IHD and CVA. Additionally, stepwise regression analysis
was used to confirm the relationships between IHD, CVA,
and clinical variables. P-values less than 0.05 were consid-
ered to be statistically significant.
Results
A total of 152 cardiovascular events (IHD and CVA) and
17 deaths due to other etiologies occurred during the 2-
year study period. IHD and CVA occurred at rates of 7.9
and 7.2 per 1000 person-years, respectively. Table 1
shows the baseline characteristics of the four patient
groups. In the NF group, fasting blood glucose levels, dia-
stolic blood pressure readings and the female/male ratio
were higher among patients using insulin than among
patients not using insulin. Conversely, LDL-C was lower
and HDL-C tended to be higher among patients using
insulin than those not using insulin in the NF group. In
the NP group, triglyceride and LDL-C levels were lower
and HDL-C levels were higher among patients using
insulin. In both the NF and NP groups, the history of dia-
betes was longer for patients using insulin. In both the
OF and OP groups, the duration of diabetes was not dif-
ferent for insulin users compared to non-users. In the
OP group, more females than males used insulin. We
adjusted the data for these baseline differences in the fol-
lowing analyses.
Multiple regression analysis examining the relationship
between the risk of IHD and clinical variables for each
group divided by age and glucose control
Table 2 shows the relationship between IHD and each
clinical measurement, such as LDL-C level and insulin
treatment for each group divided by age and glucose con-
trol levels (HbA1C). We performed multiple regression
analysis for variables that showed a possible relationship
with IHD risk by univariate analysis (P < 0.1).
Patients 70 years of age or younger: Univariate analysis
revealed that higher systolic blood pressure, higher LDL-
C and lower HDL-C were associated with IHD risk
among patients in the NF group. However, only systolic
blood pressure (OR = 1.81, 95% CI = 1.19-2.93; p =
0.009) and HDL-C level (OR = 0.46, 95% CI = 0.26-0.85;
p = 0.006) were confirmed to be significantly associated
with IHD risk by the multiple regression analysis.
Patients over 70 years of age: Lower diastolic blood
pressure was associated with IHD risk among patients in
the OF group (OR = 0.65, 95% CI = 0.48-0.96; p = 0.016).
Insulin use was significantly associated with IHD risk in
the OP group (OR = 2.27, 95% CI = 1.11-5.89; p = 0.026)
(Table 2). The duration of diabetes did not affect IHD
risk in either group.
Multiple regression analysis examining the relationship
between clinical variables and the risk of CVA for each
group divided by age and glucose control
Table 3 shows the relationship between CVA and each
clinical measurement as well as the insulin treatment
for each group.
Patients 70 years of age or younger: CVA tended to
occur more frequently among patients with higher
HbA1C levels than in those with lower HbA1C levels (OR
= 4.11, 95% CI = 1.01-13.4; p = 0.067) in the NF group.
Lower HDL-C (OR = 0.43, 95% CI = 0.23-0.78; p = 0.006)
and a longer duration of diabetes (OR = 1.06, 95% CI =
1.01-1.11; p = 0.018) were associated with CVA risk
among patients in the NP group.
Patients over 70 years of age: Insulin use was asso-
ciated with CVA risk in the OF group (OR = 2.09, 95%
CI = 1.06-4.25; p = 0.028) (Table 2). Univariate analysis
revealed a trend toward an association between lower
HDL-C levels and CVA in the OF and OP groups, but
this association was not statistically significant according
to the results of the multiple regression analysis.
Stepwise regression analysis
Stepwise multiple regression analyses were also per-
formed separately for IHD and CVA risks. The results
were very similar to those of the multiple regression ana-
lyses described above, except that LDL-C was associated
with IHD in the NF group (Table 3).
Regarding IHD risk, higher systolic blood pressure (p =
0.003), lower HDL-C (p = 0.017), and higher LDL-C (p =
0.035) were all associated with IHD risk in the NF group.
Insulin use (p = 0.005) and age (p = 0.015) were signifi-
cantly associated with IHD in the OP group.
Regarding CVA risk, higher levels of hemoglobin A1C
were associated with CVA risk in the NF group (p = 0.03),
and lower HDL-C (p = 0.004) and the duration of diabetes
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Insulin use (p = 0.038) was associated with CVA risk
among patients in the OF group. Lower HDL-C levels
tended to be associated with CVA in the OF group (p =
0.056) and the OP group (p = 0.08), although these asso-
ciations were not statistically significant.
Influence of insulin therapy on IHD and CVA risk
The results indicated that insulin therapy was associated
with IHD risk in the OP group and with CVA risk in
the OF group (Figure 2). Interestingly, patients 70 years
of age or younger who used insulin tended to have
slightly decreased incidences of IHD and CVA, whereas
patients over 70 years of age using insulin tended to
have an increased incidence of CVA (Figure 2a and 2b).
Interestingly, insulin use was associated with IHD in the
MP group (OR = 4.11, 95% CI = 1.22-8.12; p = 0.018) and
with CVA in the FP group (OR = 3.26, 95% CI = 1.12-
6.24; p = 0.02).
Multiple regression analysis examining the relationship
between clinical variables and the risk of IHD for each
group divided by gender and glucose control
Multiple regression analysis was performed to evaluate
the relationship between IHD and each clinical measure-
ment, such as LDL-C level and insulin treatment for
Table 1 Base line profile of patients
HbA1C = < 7.0 (Gp.MF) HbA1C 7.0 < (Gp.MP)
= < 70y.o. Insulin (-) Insulin (+) P Insulin (-) Insulin (+) P
Mean(SD) Mean(SD) Mean(SD) Mean(SD)
Duration of Diabetes (yrs) 6.67 (7.50) 12.18 (9.31) 0.012* 9.53(8.05) 12.48 (8.15) 0.011*
FBS (mg/dl) 145.2 (44.4) 158.2 (55) 0.022* 183.7(63.4) 173.7(71) 0.134
SBP (mmHg) 134.4 (15.5) 133.4 (17.6) 0.409 133.4(17.7) 132.7 (18.3) 0.893
DBP (mmHg) 77 (12.3) 73.2 (14.8) 0.011* 76 (10.9) 73.4(11) 0.04*
TG (mg/dl) 148.3(119.9) 135.5 (65.3) 0.844 154.1(111.6) 141.9 (184) 0.03*
HDL-C(mg/dl) 55(14.2) 57.2 (15.1) 0.062 52.8(13.4) 59.7(21.5) 0.001**
LDL-C(mg/dl) 116.3(31.9) 110.5 (27.9) 0.034* 123.4(35.9) 120.2(33.3) 0.52
%% P %% P
Gender (Male/total) 61.8 49.6 0.011* 53.3 47.5 0.116
Anti-hyperlipidemic drugs 53.9 49.3 0.131 52.7 58.6 0.477
statin 41.4 39.0 0.122 48.5 45.7 0.444
Oral diabetic drugs 44.4 10 < 0.001** 82.0 6.7 < 0.001**
sulfonylurea 43.0 9.0 < 0.001** 79.4 8.6 < 0.001**
Anti-hypertensive drugs 66.1 47.9 0.042* 54.8 51.0 0.921
70 +y.o. HbA1C = < 7.0 (Gp.OF) HbA1C 7.0 < (Gp.OP)
Insulin (-) Insulin (+) P Insulin (-) Insulin (+) P
Mean(SD) Mean(SD) Mean(SD) Mean(SD)
Duration of Diabetes (yrs) 10.83 (8.75) 12.2 (9.67) 0.12 10.67 (9.17) 11.0 (9.50) 0.43
FBS (mg/dl) 146.2 (47.1) 159.1 (59) 0.052 174.5 (70.5) 181.7 (75.5) 0.224
SBP (mmHg) 136.2 (16.4) 135.7 (17) 0.896 136.4 (15.9) 136.2 (17) 0.822
DBP (mmHg) 71.7 (11.2) 70.4 (11.6) 0.256 73.1 (11.3) 73.1 (11.1) 0.832
TG (mg/dl) 127.5 (73.4) 124.3 (75.3) 0.168 130.8 (75) 124.6 (69.3) 0.53
HDL-C (mg/dl) 55.1 (16) 55 (17.3) 0.953 54.7 (16.1) 54.7 (16.5) 0.888
LDL-C (mg/dl) 114.1 (29) 112.3 (30.3) 0.704 118.2 (30.7) 117.8 (33.6) 0.541
%% P %% P
Gender (Male/total) 54 45.9 0.061 53.2 37.9 0.035*
Anti-hyperlipidemic drugs 50.2 46.0 0.140 46.7 50 0.307
statin 43.9 40.2 0.003** 43.3 42.5 0.167
Oral diabetic drugs 62.6 18.5 < 0.001** 84.6 19.1 < 0.001**
sulfonylurea 60.1 12.6 < 0.001** 79.4 8.0 < 0.001**
Anti-hypertensive drugs 68.2 59.9 0.904 60.9 54.6 0.370
Characteristics of the patients in each of the four groups, including insulin use. These groups were stratified by glycemic control and age.
*p < 0.05, **p < 0.01.
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IHD = < 70 y.o. Mean(SD) Hgb A1C = < 7.0 (Gp.MF) 7.0 < HgbA1C (Gp.MP)
Number of events 17 15
Univariate Multivariate Univariate Multivariate
Male/Female 0.96 0.75 (0.40-1.37) 1.03 (0.62-1.74)
Age (y.o.) 60.9(7.9)y.o. 1.06 (0.98-1.20) 1.03 (0.96-1.13)
Duration of diabetes (years) 9.15(8.22) 1.04
+ (0.99-1.09) 1.03 (0.96-1.08)
Hemoglobin A1C(%) 7.38(1.31) 1.16 (0.40-4.37) 1.01 (0.60-1.50)
Triglyceride (mg/dl) 146.9(129.5) 1.01 (0.99 - 1.03) 1.01 (0.94-1.04)
LDL-Chol (mg/dl) 119.2(34.1) 1.13* (1.01-1.28) 1.12
+(1.00-1.28) 1.04 (0.87-1.21)
HDL-Chol (mg/dl) 55.4(16.2) 0.54* (0.29-0.91) 0.46*(0.26-0.85) 0.78 (0.53-1.08)
Systolic BP(mmHg) 133.5(17.5) 1.58* (1.11-2.24) 1.81**(1.19-2.93) 1.07 (0.80-1.49)
Diastolic BP (mmHg) 75.5(11.7) 0.94 (0.63-1.58) 0.96 (0.63-1.62)
Insulin user (%) 32.80% 0.96 (0.37-1.93) 1.06 (0.61-1.81)
IHD 70 < y.o. Mean(SD) Hgb A1C = < 7.0 (Gp.OF) 7.0 < HgbA1C (Gp.OP)
Number of events 25 25
Univariate Multivariate Univariate Multivariate
Male/Female 1 1.12 (0.71-1,81) 1.41 (0.83-2.97)
Age (y.o.) 75.4(4.3) 0.99 (0.88-1.09) 0.83 (0.66-0.99)
Duration of diabetes (years) 10.18(9.08) 1.02 (0.98-1.06) 1.02 (0.93-1.08)
Hemoglobin A1C (%) 7.26 (1.15) 1.74 (0.65-5.55) 1.37 (0.77-2.16)
Triglyceride (mg/dl) 129.2 (62.2) 1.00 (1.00-1.09) 1.01 (0.99-1.04)
LDL-Chol (mg/dl) 116.1 (30.6) 0.99 (0.78-1.11) 1.05 (0.87-1.24)
HDL-Chol (mg/dl) 54.7 (16.2) 0.99 (0.73-1.26) 0.79 (0.50-1.18)
Systolic BP (mmHg) 135.9 (17.1) 0.86 (0.69-1.12) 0.88 (0.61-1.25)
Diastolic BP (mmHg) 72.2 (10.9) 0.65* (0.46-0.95) 0.65*(0.46-0.95) 0.98 (0.59-1.78)
Insulin user (%) 33.90% 0.97 (0.51-1.64) 3.48*(1.42-15.24) 3.48*(1.42-15.24)
CVA = < 70 y.o. Mean(SD) Hgb A1C = < 7.0 (Gp.MF) 7.0 < HgbA1C (Gp.MP)
Number of events 17 15
Univariate Multivariate Univariate Multivariate
Male/Female 1.16 1.16 (0.65-2.26) 1.06(0.58-1.98)
Age (y.o.) 60.9 (7.9) 1.01 (0.94-1.11) 1.02(0.94-1.13)
Duration of diabetes (years) 9.15 (8.22) 0.81*(0.60-0.99) 1.08*(1.01-1.14) 1.06*(1.01-1.11)
HemoglobinA1C(%) 7.38 (1.31) 4.34*(1.07-25.8) 4.11
+(1.01-13.40) 0.77(0.35-1.35)
Triglyceride (mg/dl) 146.9(129.5) 1.00 (0.98-1.02) 1.01(0.97-1.07)
LDL-Chol (mg/dl) 119.2 (34.1) 0.99 (0.96-1.14) 0.98(0.79-1.17)
HDL-Chol (mg/dl) 55.4 (16.2) 0.78 (0.49-1.18) 0.60**(0.35-0.63) 0.43**(0.23-0.78)
Systolic BP (mmHg) 133.5 (17.5) 0.98 (0.71-1.41) 0.99(0.75-1.44)
Diastolic BP (mmHg) 75.5 (11.7) 1.26 (0.76-2.17) 1.01(0.62-1.83)
Insulin user (%) 32.80% 0.89 (0.35-1.77) 0.74(0.35-1.18)
CVA 70 < y.o. Mean(SD) Hgb A1C = < 7.0 (Gp.OF) 7.0 < HgbA1C (Gp.OP)
Number of events 16 22
Univariate Multivariate Univariate Multivariate
Male/Female 0.96 1.33 (0.79-2.40) 0.68 (0.36-1.17)
Age (y.o.) 75.4 (4.3) 1.04 (0.93-1.14) 1.05 (0.93-1.17)
Duration of diabetes (years) 10.18 (9.08) 1.01 (0.96-1.05) 1.04 (0.98-1.09)
HemoglobinA1C(%) 7.26 (1.15) 1.27 (0.47-4.29) 0.74 (035-1.32)
Triglyceride (mg/dl) 129.2 (62.2) 1.01 (0.91-1.07) 1.05 (0.97-1.19)
LDL-Chol (mg/dl) 116.1 (30.6) 0.96 (0.74-1.10) 1.04 (0.88-1.21)
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(HbA1C) (Table 4).
Male patients: IHD was associated with high systolic
blood pressure in the male/fair glycemic control group,
age in the male/poor control group. Interestingly, insulin
use was associated with IHD in the male/poor group (OR
= 4.11, 95% CI = 1.22-8.12; p = 0.018).
Female patients: IHD was associated with a short
duration of diabetic history in the female/fair and
female/poor groups.
Multiple regression analysis examining the relationship
between clinical variables and the risk of CVA for each
group divided by gender and glucose control
Multiple regression analysis was performed to evaluate
the relationship between CVA and each clinical measure-
ment and insulin treatment for each group divided by
gender and glucose control levels (HbA1C) (Table 4).
Male patients: CVA was not significantly associated
with any variables.
Female patients: CVA was associated with a short
duration of diabetic history in the female/fair and
female/poor groups. Insulin use was associated with
CVA in the female/poor group (OR = 3.26, 95% CI =
1.12-6.24; p = 0.02).
Discussion
In the present study, IHD was associated with a higher
systolic blood pressure and a lower HDL-C in patients in
the 70 years of age or younger patients with fair glycemic
control and a lower diastolic blood pressure in older
patients with fair glycemic control. Insulin use was asso-
ciated with IHD in the OP group, whereas it was asso-
ciated with CVA in the OF group. CVA was associated
with lower HDL-C and a longer duration of diabetes in
patients in the NP group. The results obtained by step-
wise analysis were similar, except that LDL-C was asso-
ciated with IHD in patients in the NP group. In the
elderly, insulin use and glycemic control may contribute
differently to IHD and CVA risks.
The frequency of diabetes increases with age, and there
are many elderly diabetic individuals. However, the risk
factors for IHD and CVA have not been clearly defined
in elderly diabetics. Furthermore, there is insufficient
clinical evidence regarding the effects of insulin therapy
on IHD and CVA risks in elderly patients [13,14]. There-
fore, this study examined the effect of insulin therapy on
IHD and CVA risks among elderly diabetics. This study
also examined the possibility that IHD and CVA risk fac-
tors varied by age.
In the present study, differences in the IHD and CVA
risks by gender were not evident. IHD was associated
with high systolic blood pressure in the MF group, age
in the MP control, short duration of diabetic history in
the FF and FP groups. Insulin use was associated with
IHD in the MP group and with CVA in the FP group
(OR = 3.26, 95% CI = 1.12-6.24; p = 0.02). CVA was
associated with short duration of diabetes in both female
groups.
IHD risk factors
American guidelines for diabetic control suggest that dia-
betic individuals under 70 years of age have a risk of devel-
oping IHD similar to that for non-diabetic individuals
Table 2 The relationship between IHD, CVA and clinical variables (Continued)
HDL-Chol (mg/dl) 54.7 (16.2) 0.61*(0.38-0.93) 0.71*(0.47-1.02) 0.71
+(0.49-1.02)
Systolic BP (mmHg) 135.9 (17.1) 0.80 (0.64-1.04) 1.25 (0.91-1.72)
Diastolic BP (mmHg) 72.2 (10.9) 0.83 (0.55-1.34) 1.09 (0.68-1,85)
Insulin user (%) 33.90% 1.93* (1.05-3.62) 1.93* (1.05-3.62) 1.11 (0.53-2.24)
+P < 0.1, *P < 0.05, **P < 0.01
Clinical characteristics of diabetic individuals and the results of the univariate and multiple regression analyses examining the association between various clinical
variables and IHD and CVA risk with stratification by age group. Patients were divided into two age categories: ≤ 70 years of age vs. > 70 years of age. Odds
ratios and the corresponding 95% confidence intervals, which are in parentheses following the odds ratios, are shown. Abbreviations: Male/Female: ratio of male
patients to female patients; Hemoglobin A1C (%): glycated hemoglobin A1C; LDL-C (mg/dl): Low-density lipoprotein cholesterol; HDL-C (mg/dl): High-density
lipoprotein cholesterol; Systolic BP (mmHg): systolic blood pressure; Diastolic BP (mmHg): diastolic blood pressure.
Bold characters indicate that a factor was found to be statistically significant by the univariate or multivariate regression analyses (p < 0.05).
Table 3 The stepwise multiple regression analyses to the
onset of IHD or CVA
Ischemic Heart Diseases
= < 70 y.o. HbA1C = < 7.0 (Gp.MF) Systolic BP 0.016*
HDL-C 0.035*
LDL-C 0.049*
Gender 0.036*
7.0 < HbA1C (Gp.MP) None
70 y.o. < HbA1C = < 7.0 (Gp.OF) Diastolic BP 0.033*
7.0 < HbA1C (Gp. OP) Insulin 0.006**
Age 0.016*
Cerebrovascular Attacks (Stroke)
= < 70 y.o. HbA1C = < 7.0 (Gp.MF) (HbA1C 0.059)
7.0 < HbA1C (Gp.MP) HDL-C 0.028*
70 y.o. < HbA1C = < 7.0 (Gp.OF) Insulin 0.028*
(HDL-C 0.086)
7.0 < HbA1C (Gp. OP) None
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Page 7 of 12having a prior myocardial infarction [8], and the results
from the present study support this concept (Figure 2).
We found that the incidence of IHD among diabetic Japa-
nese was relatively high and comparable with that of IHD
in Western countries, such as the U.K. [3,15]. The inci-
dence of IHD in our study was approximately three times
higher than the incidence rates previously reported in
Japanese trials, such as Mega study investigating patients
under 70 years of age, not all of whom had diabetes
[16,17].
In the present study, among diabetic individuals in the
NF group, higher systolic blood pressure and lower
HDL-C were associated with a risk of IHD. Systolic
blood pressure, not diastolic pressure, was confirmed as
a classical IHD risk factor from previous studies [18-20].
The age of diabetic patients in those reports was less
(a)  IHD: younger than or 70y.o. (b)  IHD: older than 70y.o.
(c)  CVA: younger than or 70y.o. (d)  CVA: older than 70y.o.
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Figure 2 Effects of age and insulin therapy on the risk of IHD and CVA among diabetic patients stratified by glycemic control
(measured by hemoglobin A1C, stratified as ≤ 7.0% vs. > 7.0%). Incidence of ischemic heart disease (IHD), left column, and cerebrovascular
accident (CVA), right column. Patients with lower hemoglobin A1C values, upper column, and higher hemoglobin A1C values, lower column. (a)
Incidence of ischemic heart disease (IHD) (≤ 70 years of age). (b) Incidence of ischemic heart disease (IHD) (> 70 years of age). (c) Incidence of
stroke (CVA) (≤ 70 years of age). (d) Incidence of stroke (CVA) (> 70 years of age). These data were adjusted for age and gender. *p < 0.05 Blue
column: subjects using insulin. Red column: subjects not using insulin.
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Page 8 of 12Table 4 The relationship on gender between IHD and clinical variables
IHD: Male Mean(SD) Hgb A1C = < 7.0 (Gp.MF) 7.0 < HgbA1C (Gp.MP)
Number of patients 1037 1022
Number of events 20 26
Univariate Multivariate Univariate Multivariate
Age (y.o.) 60.9 (7.9) 1.06 (0.97-1.19) 1.10*(1.01-1.22) 1.11*(1.02-1.25)
Duration of diabetes (years) 9.15 (8.22) 1.07(0.98-1.15) 1.09
+(0.99-1.18)
HemoglobinA1C(%) 7.38 (1.31) 1.25(0.44-4.60) 1.34(0.72-2.33)
Triglyceride (mg/dl) 146.9(129.5) 1.00 (0.98-1.01) 1.00(0.98-1.01)
LDL-Chol (mg/dl) 119.2 (34.1) 1.01 (0.99-1.04) 1.02
+(1.00-1.04)
HDL-Chol (mg/dl) 55.4 (16.2) 0.97 (0.92-1.03) 0.99(0.95-1.02)
Systolic BP (mmHg) 133.5 (17.5) 1.06* (1.02-1.11) 1.06* (1.02-1.11) 0.99(0.94-1.04)
Diastolic BP (mmHg) 75.5 (11.7) 0.95 (0.89-1.02) 1.03(0.95-1.12)
Insulin user (%) 32.80% 1.74 (0.55-2.77) 4.01**(1.15-7.38) 4.11**(1.19-8.12)
IHD:Female Mean(SD) Hgb A1C = < 7.0 (Gp.OF) 7.0 < HgbA1C (Gp.OP)
Number of patients 816 1140
Number of events 19 17
Univariate Multivariate Univariate Multivariate
Age (y.o.) 75.4 (4.3) 1.00 (0.96-1.06) 0.99 (0.95-1.05)
Duration of diabetes (years) 10.18 (9.08) 0.96*(0.93-0.98) 0.96*(0.93-0.98) 0.92*(0.84-0.99) 0.92*(0.84-0.99)
HemoglobinA1C(%) 7.26 (1.15) 1.01 (0.78-1.31) 0.84 (0.61-1.10)
Triglyceride (mg/dl) 129.2 (62.2) 1.01 (0.95-1.07) 0.99 (0.96-1.02)
LDL-Chol (mg/dl) 116.1 (30.6) 1.00 (0.98-1.03) 1.00 (0.95-1.05)
HDL-Chol (mg/dl) 54.7 (16.2) 0.97(0.92-1.02) 0.92(0.80-1.03)
Systolic BP (mmHg) 135.9 (17.1) 1.04 (0.92-1.16) 1.05 (0.91-1.18)
Diastolic BP (mmHg) 72.2 (10.9) 0.93 (0.85-1.03) 1.05 (0.94-1.15)
Insulin user (%) 33.90% 1.08
+(1.01-1.15) 6.27
+(0.91-14.24)
CVA: Male Mean(SD) Hgb A1C = < 7.0 (Gp.MF) 7.0 < HgbA1C (Gp.MP)
Number of events 22 16
Univariate Multivariate Univariate Multivariate
Age (y.o.) 60.9 (7.9) 0.99 (0.92-1.08) 1.05(0.92-1.25)
Duration of diabetes (years) 9.15 (8.22) 1.03
+(0.99-1.06) 1.01(0.99-1.02)
HemoglobinA1C(%) 7.38 (1.31) 1.68(0.74-4.33) 0.92(0.72-1.24)
Triglyceride (mg/dl) 146.9(129.5) 1.00 (0.98-1.01) 0.99(0.97-1.01)
LDL-Chol (mg/dl) 119.2 (34.1) 1.01 (0.99-1.04) 1.02(0.98-1.05)
HDL-Chol (mg/dl) 55.4 (16.2) 0.96
+(0.91-1.01) 0.99(0.92-1.05)
Systolic BP (mmHg) 133.5 (17.5) 1.01 (0.95-1.06) 0.99(0.92-1.08)
Diastolic BP (mmHg) 75.5 (11.7) 0.96 (0.90-1.05) 1.05(0.93-1.22)
Insulin user (%) 32.80% 4.44 (0.35-6.77) 1.01(0.35-1.18)
CVA:Female Mean(SD) Hgb A1C = < 7.0 (Gp.OF) 7.0 < HgbA1C (Gp.OP)
Number of events 11 21
Univariate Multivariate Univariate Multivariate
Age (y.o.) 75.4 (4.3) 1.00 (0.93-1.12) 1.35*(1.00-1.85)
Duration of diabetes (years) 10.18 (9.08) 0.97*(0.95-0.99) 0.97*(0.95-0.99) 0.94*(0.88-0.98) 0.95*(0.89-0.99)
HemoglobinA1C(%) 7.26 (1.15) 7.48 (0.70-22.8) 0.94 (0.65-1.30)
Triglyceride (mg/dl) 129.2 (62.2) 1.01 (0.91-1.07) 1.01 (0.97-1.03)
LDL-Chol (mg/dl) 116.1 (30.6) 0.96 (0.74-1.10) 1.02 (0.99-1.05)
HDL-Chol (mg/dl) 54.7 (16.2) 0.99(0.92-1.05) 0.99(0.94-1.03)
Systolic BP (mmHg) 135.9 (17.1) 1.02 (0.90-1.10) 0.88 (0.76-0.97)
Diastolic BP (mmHg) 72.2 (10.9) 1.03 (0.94-1.17) 1.02 (0.91-1.16)
Insulin user (%) 33.90% 0.93 (0.75-1.12) 3.26*(1.12-6.24) 3.29*(1.13-6.42)
+P < 0.1, *P < 0.05, **P < 0.01
Clinical characteristics of diabetic individuals and the results of the univariate and multiple regression analyses examining the association between various clinical
variables and IHD and CVA risk with stratification by gender group. Odds ratios and the corresponding 95% confidence intervals, which are in parentheses
following the odds ratios, are shown.
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Page 9 of 12than 70. Stepwise regression analysis confirmed the
association of high LDL-C and low HDL-C with a risk
of IHD in the NF group; however, the significance of
the LDL-C association was not confirmed by multiple
regression analysis [21]. The use of anti-dyslipidemia
agents, such as statins, with their pleiotropic effect may
affect this difference [21]. Insulin use tended to decrease
the incidence of IHD in patients in the NF group
(Table 2).
Among older diabetic individuals with fair glycemic
control (the OF group), lower diastolic blood pressure
was associated with IHD. Insulin use was associated
with IHD in the OP group. Coronary circulation
depends on diastolic blood flow, and the isolated systolic
hypertension (with lower diastolic blood pressure) values
may reflect aortic atherosclerosis, which is common
among the elderly.
Interestingly, insulin therapy was associated with IHD
in the OP group. The duration of diabetes was longer
among insulin users than among non-users in the NF
and NP groups; however, there was no difference in dia-
betes duration between the OF compared to the OP
group. Overall, the combination of higher plasma glucose
and insulin use may progress atherosclerosis and subse-
quently increase the risk of IHD among elderly diabetic
individuals. However, maintaining good glycemic control
via insulin use could help prevent IHD. Because patients
with a history of IHD and/or CVA were excluded from
the study, few patients in our cohort used antiplatelet
agents (< 10% of patients).
Conversely, IHD was associated with high systolic blood
pressure in the MF group, age in the MP control, and
short duration of diabetic history in the FF and FP groups.
Insulin use was associated with IHD in the male/poor
group. Females usually develop complications of athero-
sclerotic diseases, such as IHD or CVA, 10-15 years later
than males [22], which may partially be due to the preven-
tion of atherosclerosis progression by estrogen. However,
previous reports have indicated that gender does not affect
the age of onset of atherosclerotic disease in individuals
with diabetes [23,24]. Our observation that a short duration
of diabetic history is associated with IHD and CVA in
females may reflect these phenomena. A detailed mechan-
ism was not obvious in the present study and should be
evaluated in future research. Regarding gender differences
and laboratory findings in Japanese populations, it was
recently suggested that hsCRP levels increase continuously
across the fasting plasma glucose (FPG) spectrum, starting
from the lowest FPG in both men and women, but the
increase in hsCRP levels is greater in women than men.
Moreover, higher CRP gamma-glutamyl transferase (GGT)
levels are synergistically associated with the metabolic syn-
drome and insulin resistance, independently of other con-
founding factors in the general population [25,26].
CVA risk factors
The incidence of CVA is higher in East Asian individuals,
such as the Japanese, than in Caucasians. Thus, the inci-
dence of CVA was higher in the present study than those
reported in previous Western studies, but it was compar-
able to that observed in prior Japanese studies, such as
JDCS [27]. The differences in eating habits, diabetic com-
plications, and older average age observed in the present
study may have led to these differences.
Among patients in the NP group, low HDL-C was
associated with CVA. This result is consistent with pre-
vious reports; however, the relationship between the
HDL-C level and CVA has been described recently
[9,28].
Among patients in the OF group, insulin use was asso-
ciated with CVA (OR = 2.09). Although the underlying
mechanism is still unknown and the higher frequency of
CVA in Japan may affect the data, our preliminary find-
ings show that hypoglycemia occurred more frequently
among individuals in the OF group than those in the OP
group. Hypoglycemia increases stroke risk [5,29]. In the
strict glucose control group of the ACCORD study, mor-
bidity rates increased in the form of severe hypoglycemia
and weight gain.
In the OP group, glycemic control was worse among
insulin users than among non-users. The duration of dia-
betes did not differ between the OF and OP groups.
There has been a drastic increase in the elderly popula-
tion in the last several decades. Therefore, understanding
the characteristics of lifestyle-related diseases in the
elderly is important to maintain their good health. Post-
prandial hyperglycemia is common in the elderly, and
hyperosmolar nonketotic hyperglycemia often compli-
cates the course of diabetes in the elderly. Insulin therapy
reduces glucose toxicity and is necessary in some elderly
diabetic patients. Strict blood glucose control including
insulin therapy is necessary to prevent the progression of
diabetic microangiopathies. However, insulin induces
smooth muscle cell proliferation and may lead to the pro-
gression of atherosclerosis [30]. Muis et al. focused on
type 1 diabetes patients (instead of type 2) to minimize
the effects of insulin resistance [31]. They found that the
cumulative dose of regular insulin was significantly
related to carotid intima-media thickness. They observed
a similar relationship between the use of intermediate-
acting insulin with carotid intima-media thickness and
concluded that the cumulative dose of insulin was a risk
factor for atherosclerosis. Insulin contributes to cellular
senescence and causes aging in organisms, such as mice
[32,33]. The detrimental effects of insulin therapy, such
as hypoglycemia leading to stroke, was more evident in
the elderly in the present study. Unfortunately, a detailed
analysis was not possible because of the fact that patients’
insulin regimens (dose and type of insulin) change
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Page 10 of 12frequently. Future studies should examine the effects of
insulin. CVA was associated with short duration of dia-
betes in the FF and FP groups, and insulin use was asso-
ciated in the FP group. The results that short duration of
diabetic history is associated with CVA in the female may
be explained similarly as to IHD, as drastic effect of
menopause [34].
Limitations
Treatment for diabetes was based on data recorded at
the time of enrollment. Patients were followed for 2
years, and we could not analyze the detailed mechan-
isms underlying insulin therapy on the risk of IHD and
CVA.
Conclusions
The present study suggests that the risk factors for IHD
and CVA in diabetic individuals change with age and
gender and perhaps with a patient’sd e g r e eo fg l y c e m i c
control. Insulin use has a potential role in preventing
IHD but may also be a risk factor for CVA among the
diabetic elderly. Therefore, although the treatment of
diabetes is obviously important, insulin therapy for gly-
cemic control should be carefully considered in those
elderly patients. Treatment modalities that reduce the
adverse effects of insulin without sacrificing its glycemic
controlling effects would be of particular interest in the
treatment of elderly diabetic individuals.
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